Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

Mihai Gheorghiade, Cesare Orlandi, John C Jr. Burnett, David Demets, Liliana Grinfeld, Aldo Maggioni, Karl Swedberg, James E. Udelson, Faiez Zannad, Christopher Zimmer, Naveen Luke Pereira

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Background: Hospitalizations for worsening heart failure due to fluid overload (congestion) are common. Agents that treat congestion without causing electrolyte abnormalities or worsening renal function are needed. Tolvaptan is an oral vasopressin (V2) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Methods and Results: Patients are eligible for inclusion if they have a reduced left ventricular ejection fraction and are hospitalized for worsening heart failure with evidence of systemic congestion. Patients are randomized 1:1 to tolvaptan 30 mg/day or matching placebo for a minimum of 60 days. Time to all-cause mortality and time to cardiovascular mortality or heart failure hospitalization are the coprimary end points. Patient-assessed global clinical status and quality of life are also evaluated. EVEREST will be continued until 1065 deaths occur. As of April 18, 2005, 2260 patients have been enrolled. Conclusion: Tolvaptan has been shown to reduce body weight in patients with worsening heart failure without inducing renal dysfunction or causing hypokalemia. The results of EVEREST will determine whether these effects translate into improved clinical outcomes.

Original languageEnglish (US)
Pages (from-to)260-269
Number of pages10
JournalJournal of Cardiac Failure
Volume11
Issue number4
DOIs
StatePublished - May 2005

Fingerprint

Vasopressins
Heart Failure
Placebos
Outcome Assessment (Health Care)
Hypokalemia
Kidney
Mortality
Hospitalization
Body Weight
tolvaptan
Stroke Volume
Electrolytes
Quality of Life
Urine
Morbidity

Keywords

  • Clinical trials
  • Heart failure
  • Morbidity
  • Mortality
  • Vasopressin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure : Outcome study with Tolvaptan (EVEREST). / Gheorghiade, Mihai; Orlandi, Cesare; Burnett, John C Jr.; Demets, David; Grinfeld, Liliana; Maggioni, Aldo; Swedberg, Karl; Udelson, James E.; Zannad, Faiez; Zimmer, Christopher; Pereira, Naveen Luke.

In: Journal of Cardiac Failure, Vol. 11, No. 4, 05.2005, p. 260-269.

Research output: Contribution to journalArticle

Gheorghiade, Mihai ; Orlandi, Cesare ; Burnett, John C Jr. ; Demets, David ; Grinfeld, Liliana ; Maggioni, Aldo ; Swedberg, Karl ; Udelson, James E. ; Zannad, Faiez ; Zimmer, Christopher ; Pereira, Naveen Luke. / Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure : Outcome study with Tolvaptan (EVEREST). In: Journal of Cardiac Failure. 2005 ; Vol. 11, No. 4. pp. 260-269.
@article{6f5eee06a93b42d5bea5fc79bf3241ad,
title = "Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)",
abstract = "Background: Hospitalizations for worsening heart failure due to fluid overload (congestion) are common. Agents that treat congestion without causing electrolyte abnormalities or worsening renal function are needed. Tolvaptan is an oral vasopressin (V2) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Methods and Results: Patients are eligible for inclusion if they have a reduced left ventricular ejection fraction and are hospitalized for worsening heart failure with evidence of systemic congestion. Patients are randomized 1:1 to tolvaptan 30 mg/day or matching placebo for a minimum of 60 days. Time to all-cause mortality and time to cardiovascular mortality or heart failure hospitalization are the coprimary end points. Patient-assessed global clinical status and quality of life are also evaluated. EVEREST will be continued until 1065 deaths occur. As of April 18, 2005, 2260 patients have been enrolled. Conclusion: Tolvaptan has been shown to reduce body weight in patients with worsening heart failure without inducing renal dysfunction or causing hypokalemia. The results of EVEREST will determine whether these effects translate into improved clinical outcomes.",
keywords = "Clinical trials, Heart failure, Morbidity, Mortality, Vasopressin",
author = "Mihai Gheorghiade and Cesare Orlandi and Burnett, {John C Jr.} and David Demets and Liliana Grinfeld and Aldo Maggioni and Karl Swedberg and Udelson, {James E.} and Faiez Zannad and Christopher Zimmer and Pereira, {Naveen Luke}",
year = "2005",
month = "5",
doi = "10.1016/j.cardfail.2005.03.009",
language = "English (US)",
volume = "11",
pages = "260--269",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure

T2 - Outcome study with Tolvaptan (EVEREST)

AU - Gheorghiade, Mihai

AU - Orlandi, Cesare

AU - Burnett, John C Jr.

AU - Demets, David

AU - Grinfeld, Liliana

AU - Maggioni, Aldo

AU - Swedberg, Karl

AU - Udelson, James E.

AU - Zannad, Faiez

AU - Zimmer, Christopher

AU - Pereira, Naveen Luke

PY - 2005/5

Y1 - 2005/5

N2 - Background: Hospitalizations for worsening heart failure due to fluid overload (congestion) are common. Agents that treat congestion without causing electrolyte abnormalities or worsening renal function are needed. Tolvaptan is an oral vasopressin (V2) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Methods and Results: Patients are eligible for inclusion if they have a reduced left ventricular ejection fraction and are hospitalized for worsening heart failure with evidence of systemic congestion. Patients are randomized 1:1 to tolvaptan 30 mg/day or matching placebo for a minimum of 60 days. Time to all-cause mortality and time to cardiovascular mortality or heart failure hospitalization are the coprimary end points. Patient-assessed global clinical status and quality of life are also evaluated. EVEREST will be continued until 1065 deaths occur. As of April 18, 2005, 2260 patients have been enrolled. Conclusion: Tolvaptan has been shown to reduce body weight in patients with worsening heart failure without inducing renal dysfunction or causing hypokalemia. The results of EVEREST will determine whether these effects translate into improved clinical outcomes.

AB - Background: Hospitalizations for worsening heart failure due to fluid overload (congestion) are common. Agents that treat congestion without causing electrolyte abnormalities or worsening renal function are needed. Tolvaptan is an oral vasopressin (V2) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Methods and Results: Patients are eligible for inclusion if they have a reduced left ventricular ejection fraction and are hospitalized for worsening heart failure with evidence of systemic congestion. Patients are randomized 1:1 to tolvaptan 30 mg/day or matching placebo for a minimum of 60 days. Time to all-cause mortality and time to cardiovascular mortality or heart failure hospitalization are the coprimary end points. Patient-assessed global clinical status and quality of life are also evaluated. EVEREST will be continued until 1065 deaths occur. As of April 18, 2005, 2260 patients have been enrolled. Conclusion: Tolvaptan has been shown to reduce body weight in patients with worsening heart failure without inducing renal dysfunction or causing hypokalemia. The results of EVEREST will determine whether these effects translate into improved clinical outcomes.

KW - Clinical trials

KW - Heart failure

KW - Morbidity

KW - Mortality

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=20944445209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944445209&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2005.03.009

DO - 10.1016/j.cardfail.2005.03.009

M3 - Article

C2 - 15880334

AN - SCOPUS:20944445209

VL - 11

SP - 260

EP - 269

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 4

ER -